| lindner {LocalControl} | R Documentation |
Lindner Center for Research and Education study on Abciximab cost-effectiveness and survival
Description
The effects of Abciximab use on both survival and cardiac billing.
Format
A data frame with 996 rows and 10 columns:
- lifepres
Life years preserved post treatment: 0 (died) vs. 11.6 (survived).
- cardbill
Cardiac related billing in dollars within 12 months.
- abcix
Indicates whether the patient received Abciximab treatment: 1=yes 0=no.
- stent
Was a stent depolyed? 1=yes, 0=no.
- height
Patient height in centimeters.
- female
Patient sex: 1=female, 0=male.
- diabetic
Was the patient diabetic? 1=yes, 0=no.
- acutemi
Had the patient suffered an acute myocardial infarction witih the last seven days? 1=yes, 0=no.
- ejecfrac
Left ventricular ejection fraction.
- ves1proc
Number of vessels involved in the first PCI procedure.
References
Kereiakes DJ, Obenchain RL, Barber BL, Smith A, McDonald M, Broderick TM, Runyon JP, Shimshak TM, Schneider JF, Hattemer CR, Roth EM, Whang DD, Cocks D, Abbottsmith CW. Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am Heart J. 2000;140(4):603-610.